Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications

Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including fecal mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Nityanand, Umar, Tungki Pratama, Fahner, Anne-Fleur, Gibietis, Valdis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Commentaries and Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337487/
https://www.ncbi.nlm.nih.gov/pubmed/37431860
http://dx.doi.org/10.1080/19490976.2023.2232137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337487/
https://www.ncbi.nlm.nih.gov/pubmed/37431860
http://dx.doi.org/10.1080/19490976.2023.2232137

Ejemplares similares